תבנית:תרופה/פסלודקס - Faslodex
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L02BA Anti-estrogens |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת×× ×©×¨××¨× - I.M |
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Monotherapy :Faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.Combination Therapy with Palbociclib: Faslodex is indicated for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/פס×××קס - Faslodex | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| פס×××קס ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | ASTRA ZENECA UK LIMITED |
| ×©× ××¢× ×ר×ש×× | ASTRA ZENECA (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 10/2010. ר×ש××× ×ת×ר××: 10/2010 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: פס×××קס - Faslodex
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/פס×××קס - Faslodex}}
×:
{{תר×פ×/פס×××קס - Faslodex
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־15:33